Search

Your search keyword '"Oji, Yusuke"' showing total 492 results

Search Constraints

Start Over You searched for: Author "Oji, Yusuke" Remove constraint Author: "Oji, Yusuke"
492 results on '"Oji, Yusuke"'

Search Results

6. Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

8. Induction of WT1 (Wilms' Tumor Gene)-Specific Cytotoxic T Lymphocytes by WT1 Peptide Vaccine and the Resultant Cancer Regression

10. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

11. Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT

13. The activated conformation of integrin [beta]7 is a novel multiple myeloma-specific target for CAR T cell therapy

14. Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments

15. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1

16. T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy

17. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

19. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

20. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain

21. Serum WT1‑271 IgM antibody as a novel diagnostic marker for Gastric Cancer

22. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

24. WT1 epitope‑specific IgG and IgM antibodies for immune‑monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

25. Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

26. T cell-intrinsic vitamin A metabolism and its signaling are targets for memory T cell-based cancer immunotherapy

32. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy

33. Imaging Assessment of Tumor Response in the Era of Immunotherapy

37. Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

39. Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies

40. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone

41. Monitoring Minimal Residual Disease in Leukemia Using Real-time Quantitative Polymerase Chain Reaction for Wilms Tumor Gene (WT1)

42. The lck Promoter-Driven Expression of the Wilms Tumor Gene WT1 Blocks Intrathymic Differentiation of T-Lineage Cells

44. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues

47. Biased usage of T cell receptor β-chain variable region genes of Wilmsʼ tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors

48. CD48 as a novel molecular target for antibody therapy in multiple myeloma

49. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review

50. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

Catalog

Books, media, physical & digital resources